Kiniksa Pharmaceuticals International PLC (NAS:KNSA)
$ 22.32 0.28 (1.27%) Market Cap: 1.61 Bil Enterprise Value: 1.40 Bil PE Ratio: 0 PB Ratio: 3.69 GF Score: 58/100

Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 10:00PM GMT
Release Date Price: $13.79 (-1.57%)
Anupam Rama
JP Morgan Chase & Co, Research Division - VP and Analyst

Okay. We'll go ahead and get started. So welcome to the afternoon session of the 2020 JPMorgan Health Care Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Matt Bannon and Tess Romero from the team. Our next presenting company is Kiniksa. And presenting on behalf of the company, we have CEO, Sanj Patel. Sanj?

Sanj K. Patel
Kiniksa Pharmaceuticals, Ltd. - CEO & Chairman of the Board

Thanks, Anupam. Good afternoon. It's great to be here. This is actually the 10th time I have had the opportunity of presenting at this conference. And as usual, I want to thank JPMorgan and Anupam, for hosting us today. We have a lot to go through. So let's get started.

I'm going to start with an overview of our corporate strategy, review our pipeline and also the multiple clinical data readouts that we have coming up this year. First, please note that I will be making forward-looking statements today that are subject to risks and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot